745,964 Shares in Sionna Therapeutics, Inc. $SION Acquired by Aberdeen Group plc

Key Points

• Aberdeen Group plc invested approximately $7.80 million in Sionna Therapeutics, acquiring 745,964 shares and holding about 1.69% of the company.
• Wall Street analysts upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating, with a consensus target price of $38.50 and an overall average rating of "Buy".
• Sionna Therapeutics reported earnings of ($0.41) per share, surpassing the consensus estimate by $0.27, indicating better-than-expected financial performance.

Aberdeen Group plc purchased a new position in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 745,964 shares of the company's stock, valued at approximately $7,803,000. Aberdeen Group plc owned about 1.69% of Sionna Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SION. Jennison Associates LLC bought a new position in Sionna Therapeutics in the 1st quarter worth approximately $8,995,000. TD Asset Management Inc acquired a new position in Sionna Therapeutics in the first quarter worth approximately $579,000. CenterBook Partners LP acquired a new stake in shares of Sionna Therapeutics during the first quarter worth $1,195,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Sionna Therapeutics in the first quarter worth about $676,000.

Insider Activity

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc acquired 60,000 shares of Sionna Therapeutics stock in a transaction dated Friday, June 27th. The stock was bought at an average cost of $15.84 per share, with a total value of $950,400.00. Following the acquisition, the insider owned 6,744,962 shares of the company's stock, valued at approximately $106,840,198.08. The trade was a 0.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.90% of the company's stock.

Sionna Therapeutics Price Performance

NASDAQ:SION traded up $0.65 during trading hours on Friday, hitting $24.39. 184,624 shares of the company traded hands, compared to its average volume of 176,059. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $25.19. The stock's 50-day moving average price is $18.63.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.27.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $38.50.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.